Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect.

  2. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    mavorixafor is being investigated in these conditions. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

    Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-
  3. Drug

    Ordesekimab

    go.drugbank.com/drugs/DB16649
    Investigational

    Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).

  4. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: DL-prenylamine, N-(3,3-Diphenylpropyl)-alpha-methylphenaethylaminCategories: Vasodilators Used in Cardiac Diseases
  5. Drug

    Tarloxotinib

    go.drugbank.com/drugs/DB14944
    Investigational

    Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).

  6. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … [L36773] In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations.

  7. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  8. Drug

    Becotatug vedotin

    go.drugbank.com/drugs/DB17407
    Investigational

    MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.

  9. Drug

    Arachidonic Acid

    go.drugbank.com/drugs/DB04557
    ApprovedInvestigationalWithdrawn

    An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. … It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [PubChem]

    Mixtures: SIMILAC ALIMENTUM 400 G TOZ
  10. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.